File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: The in vitro post-antifungal effect of nystatin on Candida species of oral origin

TitleThe in vitro post-antifungal effect of nystatin on Candida species of oral origin
Authors
Issue Date1999
PublisherBlackwell Munksgaard. The Journal's web site is located at http://www.blackwellpublishing.com/journals/JOPM
Citation
Journal Of Oral Pathology And Medicine, 1999, v. 28 n. 3, p. 112-116 How to Cite?
AbstractThe post-antifungal effect (PAFE) is defined as the suppression of growth that persists following limited exposure of yeasts to antimycotics and subsequent removal of the drug. Although limited data are available on the PAFE of nystatin on oral isolates of C. albicans, there is no information on non-albicans Candida species. As nystatin is the commonest antifungal agent prescribed in dentistry, the main aim of this investigation was to measure the PAFE of oral isolates of Candida belonging to six different species (five isolates each of C. albicans, C. tropicalis, C. krusei, C. parapsilosis, C. glabrata and C. guilliermondii) following limited exposure (1 h) to nystatin. The yeasts were examined for the presence of the PAFE after 1 h exposure to the minimum inhibitory concentration (MIC) of nystatin. The PAFE was determined as the difference in time (h) required for the growth of the drug-free control and the drug-exposed test cultures to increase to the 0.05 absorbance level following removal of the antifungal agent. The mean duration of nystatin-elicited PAFE was lowest for C. albicans (6.85 h) and greatest for C. parapsilosis (15.17 h), while C. krusei (11.58 h), C. tropicalis (12.73 h), C. glabrata (8.51 h), and C. guilliermondii (8.68 h) elicited intermediate values. These findings clarify another intriguing possibility for the persistent, chronic recurrence of oral C. albicans infections despite apparently adequate antifungal drug regimens. The significant variations in nystatin-induced PAFE amongst non-albicans species may also have clinical implications, in terms of nystatin regimens used in the management of these fungal infections.
Persistent Identifierhttp://hdl.handle.net/10722/154060
ISSN
2015 Impact Factor: 1.859
2015 SCImago Journal Rankings: 0.731
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorEllepola, ANBen_US
dc.contributor.authorSamaranayake, LPen_US
dc.date.accessioned2012-08-08T08:23:04Z-
dc.date.available2012-08-08T08:23:04Z-
dc.date.issued1999en_US
dc.identifier.citationJournal Of Oral Pathology And Medicine, 1999, v. 28 n. 3, p. 112-116en_US
dc.identifier.issn0904-2512en_US
dc.identifier.urihttp://hdl.handle.net/10722/154060-
dc.description.abstractThe post-antifungal effect (PAFE) is defined as the suppression of growth that persists following limited exposure of yeasts to antimycotics and subsequent removal of the drug. Although limited data are available on the PAFE of nystatin on oral isolates of C. albicans, there is no information on non-albicans Candida species. As nystatin is the commonest antifungal agent prescribed in dentistry, the main aim of this investigation was to measure the PAFE of oral isolates of Candida belonging to six different species (five isolates each of C. albicans, C. tropicalis, C. krusei, C. parapsilosis, C. glabrata and C. guilliermondii) following limited exposure (1 h) to nystatin. The yeasts were examined for the presence of the PAFE after 1 h exposure to the minimum inhibitory concentration (MIC) of nystatin. The PAFE was determined as the difference in time (h) required for the growth of the drug-free control and the drug-exposed test cultures to increase to the 0.05 absorbance level following removal of the antifungal agent. The mean duration of nystatin-elicited PAFE was lowest for C. albicans (6.85 h) and greatest for C. parapsilosis (15.17 h), while C. krusei (11.58 h), C. tropicalis (12.73 h), C. glabrata (8.51 h), and C. guilliermondii (8.68 h) elicited intermediate values. These findings clarify another intriguing possibility for the persistent, chronic recurrence of oral C. albicans infections despite apparently adequate antifungal drug regimens. The significant variations in nystatin-induced PAFE amongst non-albicans species may also have clinical implications, in terms of nystatin regimens used in the management of these fungal infections.en_US
dc.languageengen_US
dc.publisherBlackwell Munksgaard. The Journal's web site is located at http://www.blackwellpublishing.com/journals/JOPMen_US
dc.relation.ispartofJournal of Oral Pathology and Medicineen_US
dc.subject.meshAnalysis Of Varianceen_US
dc.subject.meshAntifungal Agents - Pharmacology - Therapeutic Useen_US
dc.subject.meshCandida - Drug Effects - Growth & Developmenten_US
dc.subject.meshCandidiasis, Oral - Drug Therapy - Microbiologyen_US
dc.subject.meshHumansen_US
dc.subject.meshMicrobial Sensitivity Testsen_US
dc.subject.meshNystatin - Pharmacology - Therapeutic Useen_US
dc.subject.meshRecurrenceen_US
dc.subject.meshStatistics, Nonparametricen_US
dc.titleThe in vitro post-antifungal effect of nystatin on Candida species of oral originen_US
dc.typeArticleen_US
dc.identifier.emailSamaranayake, LP:lakshman@hku.hken_US
dc.identifier.authoritySamaranayake, LP=rp00023en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.pmid10069538-
dc.identifier.scopuseid_2-s2.0-0033104631en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0033104631&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume28en_US
dc.identifier.issue3en_US
dc.identifier.spage112en_US
dc.identifier.epage116en_US
dc.identifier.isiWOS:000078832400004-
dc.publisher.placeDenmarken_US
dc.identifier.scopusauthoridEllepola, ANB=6604060863en_US
dc.identifier.scopusauthoridSamaranayake, LP=7102761002en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats